Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders

TitleRandomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders
Publication TypeJournal Article
Year of Publication2001
AuthorsBarrowclough, C, Haddock, G, Tarrier, N, Lewis, SW, Moring, J, O'Brien, R, Schofield, N, McGovern, J
JournalAmerican Journal of Psychiatry
Volume158
Pagination1706-1713
PublisherAmerican Psychiatric Assn
Place PublishedUS
Publication Languageeng
ISBN Number0002-953X1535-7228
Accession Number2001-18994-020. First Author & Affiliation: Barrowclough, Christine
Keywordscognitive behavior therapy, Cognitive Therapy, Comorbidity, Drug abuse, family intervention, Family Therapy, integrated psychological & psychosocial treatment, Integrated Services, motivational interviewing, Multimodal Treatment Approach, Psychosocial Rehabilitation, Psychotherapeutic Techniques, Risk, Schizophrenia, substance abuse disorders
Abstract

Comorbidity of substance abuse disorders with schizophrenia is associated with a greater risk for serious illness complications and poorer outcome. Methodologically sound studies investigating treatment approaches for patients with these disorders are rare, although recommendations for integrated and comprehensive treatment programs abound. This study investigates the relative benefit of adding an integrated psychological and psychosocial treatment program to routine psychiatric care for patients with schizophrenia and substance use disorders. The authors conducted a randomized, single-blind controlled comparison of routine care (N=15) with a program of routine care integrated (N=17) with motivational interviewing, cognitive behavior therapy and family or caregiver intervention. The integrated treatment program resulted in significantly greater improvement in patients' general functioning than routine care alone at the end of treatment and 12 mo after the beginning of the study. Other benefits of the program included a reduction in positive symptoms and in symptom exacerbations and an increase in the percent of days of abstinence from drugs or alcohol over the 12-mo period from baseline to follow-up. (PsycINFO Database Record (c) 2010 APA, all rights reserved)

URLhttp://libproxy.unm.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2001-18994-020&login.asp&site=ehost-live&scope=sitehttp://ajp.psychiatryonline.org/cgi/reprint/158/10/1706.pdf
Go to top